One Health Co., whose flagship product FidoCure uses genomic testing to identify possible cancer-causing mutations in dogs and recommend a personalized therapeutic treatment, has raised $10 million from investors.
The money will be used to “accelerate the expansion” of FidoCure, the Palo Alto, California, company reported. Participating were Polaris Partners, Borealis Ventures and previous investors Andreessen Horowitz, Lerer Hippeau, Y-Combinator and Tau Ventures.
Veterinarians who use FidoCure receive guidance in selecting from 14 human-grade therapies for their oncology patients.
“Cancer care for dogs has not changed much in the last 30 years, but human cancer care has tremendously advanced, especially in the field of precision medicine,” said Christina Lopes, co-founder and CEO of One Health. “Using the same advanced cancer diagnostics and precision medicine that are currently on the market and approved by the FDA for people, we are bringing cancer care for dogs. And when we open access to precision cancer treatments for our furry friends, we build data that helps advance human oncology research and treatment.”
FidoCure is available from more than 200 U.S. veterinarians, according to One Health Co.
Over 25% of practicing veterinary oncologists in the United States have adopted FidoCure, the company added.
Did you know a subscription to Today’s Veterinary Business is free to qualified veterinary professionals? All you have to do is sign up here (and renew each year). You also can sign up to receive the Today’s Veterinary Business weekly e-newsletter.